Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
You can use these links to skip ahead to the information most pertinent to you: What Is Semaglutide
Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously
Because of this form of administration (injection), they must not be marketed as cosmetics
Used to treat rare problems like idiopathic angioneurotic edema
Elife, 2025
By choosing to buy Melanotan II from us, you are investing in a product that exemplifies the highest standards of precision and purity in peptide research
US$ 21.75
US$ 23.92
US$ 24.90
US$ 28.11
US$ 29.23
